These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 31264346

  • 1. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
    Bailey TS, Wu J, Zhou FL, Gupta RA, Menon AA, Berhanu P, Westerbacka J, Van Vleet J, Blonde L.
    Diabetes Obes Metab; 2019 Nov; 21(11):2384-2393. PubMed ID: 31264346
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Sullivan SD, Bailey TS, Roussel R, Zhou FL, Bosnyak Z, Preblick R, Westerbacka J, Gupta RA, Blonde L.
    Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
    Sullivan SD, Freemantle N, Gupta RA, Wu J, Nicholls CJ, Westerbacka J, Bailey TS.
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
    Sullivan SD, Nicholls CJ, Gupta RA, Menon AA, Wu J, Westerbacka J, Bosnyak Z, Frias JP, Bailey TS.
    Diabetes Obes Metab; 2019 Sep; 21(9):2123-2132. PubMed ID: 31144445
    [Abstract] [Full Text] [Related]

  • 7. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
    Zhou FL, Ye F, Berhanu P, Gupta VE, Gupta RA, Sung J, Westerbacka J, Bailey TS, Blonde L.
    Diabetes Obes Metab; 2018 May; 20(5):1293-1297. PubMed ID: 29272064
    [Abstract] [Full Text] [Related]

  • 8. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
    Abitbol A, Brown RE, Jiandani D, Sauriol L, Aronson R.
    Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
    [Abstract] [Full Text] [Related]

  • 9. Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.
    Blonde L, Bailey T, Sullivan SD, Freemantle N.
    Diabetes Obes Metab; 2021 Aug; 23(8):1713-1721. PubMed ID: 33881797
    [Abstract] [Full Text] [Related]

  • 10. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
    Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J.
    Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
    [Abstract] [Full Text] [Related]

  • 11. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF, Aroda VR, Charbonnel B, Sinclair AJ, Trescoli C, Cahn A, Bigot G, Merino-Trigo A, Brulle-Wohlhueter C, Bolli GB, Ritzel R.
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [Abstract] [Full Text] [Related]

  • 12. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
    Escalada J, Bonnet F, Wu J, Bonnemaire M, Gupta S, Cambron-Mellott JM, Nicholls C, Müller-Wieland D.
    Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
    [Abstract] [Full Text] [Related]

  • 13. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.
    Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J.
    Diabetes Obes Metab; 2015 Mar; 17(3):245-53. PubMed ID: 25359227
    [Abstract] [Full Text] [Related]

  • 14. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S, Wang H, Skolnik N, Tong L, Liebert RM, Lee LK, Stella P, Cali A, Preblick R.
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [Abstract] [Full Text] [Related]

  • 15. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B, Wiza D, Szczepanik T, Syta A, Klupa T.
    J Diabetes Res; 2020 Jan; 2020():8751348. PubMed ID: 32337298
    [Abstract] [Full Text] [Related]

  • 16. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
    Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC.
    Diabetes Obes Metab; 2018 Jan; 20(1):121-128. PubMed ID: 28661585
    [Abstract] [Full Text] [Related]

  • 17. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR, Traylor L, Mullins P, Landgraf W.
    Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
    [Abstract] [Full Text] [Related]

  • 18. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
    Yki-Järvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I, Maroccia M, Riddle MC.
    Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
    [Abstract] [Full Text] [Related]

  • 19. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R, d'Emden MC, Fisher M, Ampudia-Blasco FJ, Stella P, Bizet F, Cali AMG, Wysham CH.
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [Abstract] [Full Text] [Related]

  • 20. Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study.
    Kosjerina V, Carstensen B, Amadid H, Vistisen D.
    Diabetologia; 2023 Oct; 66(10):1908-1913. PubMed ID: 37505281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.